Details for Patent: 8,362,002
✉ Email this page to a colleague
Which drugs does patent 8,362,002 protect, and when does it expire?
Patent 8,362,002 protects COTELLIC and is included in one NDA.
Protection for COTELLIC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-six patent family members in thirty-two countries.
Summary for Patent: 8,362,002
| Title: | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| Abstract: | Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. |
| Inventor(s): | Aay; Naing (San Mateo, CA), Anand; Neel Kumar (Burlingame, CA), Blazey; Charles M. (San Francisco, CA), Bowles; Owen Joseph (Pacifica, CA), Bussenius; Joerg (Foster City, CA), Costanzo; Simona (Los Altos, CA), Curtis; Jeffry Kimo (San Anselmo, CA), DeFina; Steven Charles (Burlingame, CA), Dubenko; Larisa (San Francisco, CA), Joshi; Anagha Abhijit (Fremont, CA), Kennedy; Abigail R. (Oakland, CA), Kim; Angie Inyoung (San Mateo, CA), Koltun; Elena S. (Foster City, CA), Manalo; Jean-Claire Limun (Daly City, CA), Peto; Csaba J. (Alameda, CA), Rice; Kenneth D. (San Rafael, CA), Tsang; Tsze H. (El Cerrito, CA) |
| Assignee: | Exelixis, Inc. (San Francisco, CA) |
| Application Number: | 13/048,832 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,362,002
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,362,002
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E504565 | ⤷ Try a Trial | |||
| Australia | 2006302415 | ⤷ Try a Trial | |||
| Brazil | PI0617165 | ⤷ Try a Trial | |||
| Canada | 2622755 | ⤷ Try a Trial | |||
| Canada | 2927656 | ⤷ Try a Trial | |||
| Canada | 3052368 | ⤷ Try a Trial | |||
| China | 101365676 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
